janus kinase (JAK) inhibitor - living meta-analysis of clinical studies

table network network 2

demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only

	COVID 19 hospitalized
	COVID 19 all comers
janus kinase (JAK) inhibitor
baricitinib	RECOVERY

7 studies excluded by filtering options 0

6141	Rodriguez-Garcia, 2020	1	10	0		not a RCT	risk of bias not avaialble
6415	Cantini, 2020	2	31	0	excluded	not a RCT	risk of bias not avaialble
6430	Cantini, 2020	1	13	4		not a RCT	high risk of bias
6490	Kaplanski, 2020	0	30	0	selection pending
6714	DEVENT, 0	1	1	0			risk of bias not avaialble
9239	Tziolos, 2021	1	13	0		not a RCT	risk of bias not avaialble
9258	Murugesan, 2022	1	1	0			risk of bias not avaialble